Filana Therapeutics reports Q1 2026 results and progress on simufilam for TSC-related epilepsy amid FDA clinical hold.

Filana Therapeutics announced its Q1 2026 financial results, showing a net loss of $10.3 million and cash reserves of $86.6 million. The company is focused on developing simufilam, a drug candidate for TSC-related epilepsy, and is working to resolve an FDA clinical hold by submitting additional data. Recent scientific presentations and publications support simufilam's potential to reduce seizures in TSC, a rare genetic disorder affecting about 45,000 people in the U.S. Filana plans to update stakeholders as it advances the program and addresses regulatory requirements.